Multiple recombinants in two dengue virus, serotype-2 isolates from patients from Oaxaca, Mexico

Department of Genetics and Molecular Biology, Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Av, Instituto Politecnico Nacional 2508, San Pedro Zacatenco, Mexico.
BMC Microbiology (Impact Factor: 2.73). 12/2009; 9(1):260. DOI: 10.1186/1471-2180-9-260
Source: PubMed


Dengue (DEN) is a serious cause of mortality and morbidity in the world including Mexico, where the infection is endemic. One of the states with the highest rate of dengue cases is Oaxaca. The cause of DEN is a positive-sense RNA virus, the dengue virus (DENV) that evolves rapidly increasing its variability due to the absence of a repair mechanism that leads to approximately one mutational event per genome replication; which results in enhancement of viral adaptation, including the escape from host immune responses. Additionally, recombination may play a role in driving the evolution of DENV, which may potentially affect virulence and cause host tropism changes. Recombination in DENV has not been described in Mexican strains, neither has been described the relevance in virus evolution in an endemic state such as Oaxaca where the four serotypes of DENV are circulating.
To study whether there are isolates from Oaxaca having recombination, we obtained the sequence of 6 different isolates of DENV-2 Asian/American genotype from the outbreak 2005-6, one clone of the C(91)-prM-E-NS1(2400) structural genes, and 10 clones of the E gene from the isolate MEX_OAX_1656_05. Evidence of recombination was found by using different methods along with two softwares: RDP3 and GARD. The Oaxaca MEX_OAX_1656_05 and MEX_OAX_1038_05 isolates sequenced in this study were recombinant viruses that incorporate the genome sequence from the Cosmopolitan genotype. Furthermore, the clone of the E gene namely MEX_OAX_165607_05 from this study was also recombinant, incorporating genome sequence from the American genotype.
This is the first report of recombination in DENV-2 in Mexico. Given such a recombinant activity new genomic combinations were produced, this could play a significant role in the DENV evolution and must be considered as a potentially important mechanism generating genetic variation in this virus with serious implications for the vaccines and drugs formulation as occurs for other viruses like poliovirus, influenza and HIV.

Download full-text


Available from: Maria De Lourdes Munoz
  • Source
    • "A critical analysis of the phylogenetic reports of DENV recombination suggests that not only is recombination occurring in nature, but that multiple completely homologous polymerase jumps are possible, and can result in the generation of mosaic DENV genomes [31], [35]–[37]. In fact, one report by Chen et al., (2008) has identified a DENV 1 genome with three recombinant regions coincident with six homologous polymerase template switches. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recombination is a mechanism whereby positive sense single stranded RNA viruses exchange segments of genetic information. Recent phylogenetic analyses of naturally occurring recombinant flaviviruses have raised concerns regarding the potential for the emergence of virulent recombinants either post-vaccination or following co-infection with two distinct wild-type viruses. To characterize the conditions and sequences that favor RNA arthropod-borne virus recombination we constructed yellow fever virus (YFV) 17D recombinant crosses containing complementary deletions in the envelope protein coding sequence. These constructs were designed to strongly favor recombination, and the detection conditions were optimized to achieve high sensitivity recovery of putative recombinants. Full length recombinant YFV 17D virus was never detected under any of the experimental conditions examined, despite achieving estimated YFV replicon co-infection levels of ∼2.4 x 10⁶ in BHK-21 (vertebrate) cells and ∼1.05 x 10⁵ in C₇10 (arthropod) cells. Additionally YFV 17D superinfection resistance was observed in vertebrate and arthropod cells harboring a primary infection with wild-type YFV Asibi strain. Furthermore recombination potential was also evaluated using similarly designed chikungunya virus (CHIKV) replicons towards validation of this strategy for recombination detection. Non-homologus recombination was observed for CHIKV within the structural gene coding sequence resulting in an in-frame duplication of capsid and E3 gene. Based on these data, it is concluded that even in the unlikely event of a high level acute co-infection of two distinct YFV genomes in an arthropod or vertebrate host, the generation of viable flavivirus recombinants is extremely unlikely.
    Full-text · Article · Aug 2011 · PLoS ONE
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Both dengue fever and its more serious clinical manifestation, dengue hemorrhagic fever, represent major public health concerns in the Americas. To understand the patterns and dynamics of virus transmission in Mexico, a country characterized by a marked increase in dengue incidence in recent years, we undertook a molecular evolutionary analysis of the largest sample of Mexican strains of dengue virus compiled to date. Our E gene data set comprises sequences sampled over a period of 27 years and representing all of the Mexican states that are endemic for dengue. Our phylogenetic analysis reveals that, for each of the four dengue viruses (DENV-1 to DENV-4), there have been multiple introductions of viral lineages in Mexico, with viruses similar to those observed throughout the Americas, but there has been strikingly little co-circulation. Rather, dengue virus evolution in Mexico is typified by frequent lineage replacement, such that only a single viral lineage dominates in a specific serotype at a specific time point. Most lineage replacement events involve members of the same viral genotype, although a replacement event involving different genotypes was observed with DENV-2, and viral lineages that are new to Mexico are described for DENV-1, DENV-3 and DENV-4.
    Full-text · Article · Sep 2010 · Archives of Virology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dengue represents a major, growing public health problem, with an estimated of 2.5 billion people at risk of infection and about 50 million cases. Vector control is the only way of controlling dengue transmission; however, in spite of efforts, an expanded geographic extension of the vector and viruses is observed. Consequently, there is an urgent need for a safe and effective dengue vaccine. Currently, there is no licensed vaccine available, although there are several candidates in different stages of development, a few highly promising. Strategies that have been followed include inactivated viruses, conventional live attenuated vaccines, chimeric live attenuated vaccines, DNA, subunit and vectored vaccines. Advances and challenges of dengue vaccine development are updated here. Copyright © 2011 Prous Science, S.A.U. or its licensors. All rights reserved.
    No preview · Article · Jan 2011 · Drugs of the Future
Show more